魏江提出，在不确定性成为常态的背景下，浙江企业要从"被动应对"转向"主动塑造"，以非对称创新、 制度型市场等战略思维，打造具有全球竞争力的产业生态圈。 作为浙江省贸促系统聚力打造的"浙里出海"品牌重要活动，本次报告会不仅是政策解读与智慧碰撞的平 台，更成为连接政府、高校、企业的"桥梁"——300余名参会者中，不少企业代表带着实际问题而来， 在互动环节与专家深入交流，现场氛围热烈。下一步，浙江省贸促会(省国际商会)将继续贯彻落实党的 二十届四中全会精神，精准对接企业需求，优化服务体系，全力护航浙江企业在全球变局中行稳致远、 勇立潮头。 当天的报告会中，两位专家的主旨分享成为焦点，既有宏观经济分析，也有实操战略建议。邱晓华指 出，当前中国经济正处于改革开放以来第四轮困难期，面临外部冲击、动能转换与宏观政策交织的复杂 局面，需求不足与通缩压力仍是主要挑战。他建议，面对美国"对等关税"升级和全球贸易摩擦加剧，浙 江企业应加快从"成本导向"向"战略导向"转型，积极拓展新兴市场，推动产业链协同出海，提升本地化 运营与合规能力。 商报讯(记者杨伊琳)10月27日，由浙江省贸促会(省国际商会)联合浙江财经大学共同主办的"浙里 ...

Group 1 - The Chinese government has launched a national venture capital guidance fund with a scale of 1 trillion RMB, focusing on cutting-edge technology sectors such as AI, quantum technology, hydrogen energy storage, and biomanufacturing [1] - The financial asset investment company (AIC) equity investment pilot has expanded to 18 provinces, with Guangdong and Hunan leading the establishment of provincial AIC funds [1] - The optimization of exit paths for technology companies includes IPO adjustments, expansion of S fund trials, and accelerated private equity fund share transfers, enhancing capital circulation certainty [1] Group 2 - The global advanced packaging market is expected to reach $57.1 billion in 2025, with China's market growing from $35.1 billion in 2020 to $69.8 billion in 2024, achieving a compound annual growth rate of 18.7% [2] - The Chinese electric vehicle sector has seen significant growth, with production and sales reaching 6.968 million and 6.937 million units respectively in the first half of 2025, marking year-on-year increases of 41.4% and 40.3% [2] - CATL plans to invest up to 14 billion RMB to establish a core European battery base in Hungary, with an expected annual production capacity of 100 GWh by 2025 [2] Group 3 - Over 40% of the upfront payments exceeding $50 million in BD transactions by multinational pharmaceutical companies have gone to Chinese firms, indicating a strong global presence in the biopharmaceutical sector [3] - Top investment firms such as Sequoia China, Qiming Venture Partners, Hillhouse Capital, and Peakview Capital remain optimistic about the long-term value of the biopharmaceutical industry despite its high-risk nature [3] - The launch of the "Top Venture Capitalists in China" and "Top Venture Capital Institutions in China" lists aims to highlight the strengths of the venture capital ecosystem in China [3]